3,0
7 gen 2015
Dipendente anonimo
Ex dipendente
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Diversity in Oncology portfolio, very strong in oncology.
Svantaggi
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.